Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: Implications for pertuzumab sensitivity

Molecular Cancer Research

Volumn 7, Issue 9, 2009, Pages 1563-1571

  Nagumo, Yoko ^a,c   Faratian, Dana ^a   Mullen, Peter ^a   Harrison, David J ^a   Hasmann, Max ^b   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; MICE; NEUREGULIN-1; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349487546     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0101     Document Type: Article

References (29)

1. Langdon SP, Mullen P, Faratian D, et al. Pertuzumab. Drugs of The Future 2008;33:123-130
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137
3. Tanner KG, Kyte J. Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor. J Biol Chem 1999;102:35985-35990 (Pubitemid 129512909)
4. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354 (Pubitemid 40637826)
5. Olayioye MA, Neve RM, Lane NE, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167
6. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-984 (Pubitemid 47050487)
7. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137
8. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-306 (Pubitemid 26047507)
9. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712 (Pubitemid 19147683)
10. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091 (Pubitemid 20225635)
11. Meden H, Marx D, Rath W. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994;13:45-53. (Pubitemid 24006333)
12. Tuefferd M, Couturier J, Penault-Liorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO Study of 320 patients. PLoS ONE 2007;2: e1138. (Pubitemid 351597374)
13. Bookman MA, Darxy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-290 (Pubitemid 46606157)
14. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer; potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24:4324-4332 (Pubitemid 46630791)
15. Amler LS, Makhija T, Januario UA, et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol 2008;26:5552.
16. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008;314:3093-3106
17. Kaye SB, Poole CJ, Bidzinski M, et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J Clin Oncol 2008;26:5520.
18. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalling. Mol Cancer Ther 2007;6:93-100. (Pubitemid 46206671)
19. Gilmour LM, Macleod KG, McCaig A, et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin Cancer Res 2002;8:3933-3942 (Pubitemid 35424788)
20. Simpson BJ, Langdon SP, Rabiasz GJ, et al. Estrogen regulation of transforming growth factor-α in ovarian cancer. J Steroid Biochem Mol Biol 1998; 64:137-145 (Pubitemid 28200986)
21. Faratian D, Goltsov A, Lebedeva G, et al. Systems biology reveals new strategies for personalising cancer medicine and confirms PTEN's role in resistance to trastuzumab. Cancer Res 2009;69:6713-6720
22. Brockhoff G, Heckel B, Schmidt-Bruecken E, et al. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007;40:488-507.
23. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705. (Pubitemid 47073531)
24. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110 in cell growth, metabolism and tumorigenesis. Nature 2008;457:776-780
25. Tzahar E, Waterman H, Chen X, et al. A hierarchical network interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287 (Pubitemid 26315047)
26. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2- amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68: 5878-5887
27. Sakai K, Yokote H, Murakami-Murofushi K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Science 2007;98:1498-1503 (Pubitemid 47241776)
28. Langdon SP, Lawrie SS, Hay FG, et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988;48:6166-6172 (Pubitemid 18266818)
29. Board RE, Thelwell NJ, Ravetto PF, et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008;54:757-760